Your First Peptide Protocol — A Beginner's Framework

Starting a peptide protocol for the first time involves several decisions that are easier to make with a framework than by guessing. Which compound to begin with, what dose to start at, how often to administer it, what to track, and how long to run it before assessing — these are the practical questions that determine whether a first protocol produces useful data or confusion.

This guide is a structural framework. It covers the sequence of decisions involved in setting up and running a first protocol, with enough context at each step to make an informed choice. It is organized around the assumption that the reader is genuinely new to peptide use — not someone optimizing an existing stack, but someone preparing to run their first compound.

Before You Start

Before administering anything, there are a few prerequisites that make the difference between a protocol you can learn from and one that generates ambiguous results.

Have your supplies ready

Running out of supplies mid-protocol — or realizing you forgot bacteriostatic water — creates unnecessary gaps. For injectable peptides, the supply list includes:

• The compound itself — lyophilized (freeze-dried) powder in a sealed vial, from a source you have researched
• Bacteriostatic water (BAC water) — for reconstitution. Not sterile water (no preservative) and not saline
• Insulin syringes — 29-31 gauge, 0.5ml or 1ml, for SubQ injection. Enough for the entire protocol duration plus extras
• Alcohol swabs — for vial septum and injection site preparation
• Sharps container — for safe needle disposal

If you have not reconstituted a peptide before, the reconstitution guide walks through the process step by step, and the reconstitution calculator handles the math for any vial size and target dose.

Choosing Your First Compound

The single most common piece of advice from experienced users is to start with one compound. Not two, not a stack — one. The reasoning is practical: if something changes after starting a protocol (positive or negative), running a single compound means you know exactly what caused it. Stacking multiple compounds from day one makes attribution impossible.

The choice of compound is driven by goal. The most common starting points by use case:

Healing and recovery

BPC-157 is the most commonly used first peptide for healing and recovery applications. It is a synthetic fragment of a protein found in gastric juice, with a large body of preclinical research on tissue healing. It has a short half-life (~30 minutes after SubQ injection), is typically dosed daily, and most protocols run 4-8 weeks. TB-500 (Thymosin Beta-4) is often discussed alongside BPC-157 for healing, with a longer half-life (~2 hours) and broader systemic effects on cell migration and tissue remodeling.

Weight management

Semaglutide and tirzepatide are the dominant compounds for weight management protocols. Both are GLP-1 receptor agonists (tirzepatide is a dual GIP/GLP-1 agonist) with long half-lives — semaglutide at approximately 7 days, tirzepatide at approximately 5 days — enabling weekly dosing. Both require a titration schedule, starting at lower doses and increasing over weeks to manage GI tolerance. These are typically longer-term protocols with ongoing use rather than defined cycles.

Growth hormone optimization

Ipamorelin and CJC-1295 (no DAC) are commonly used first compounds for GH secretagogue protocols. Ipamorelin is a selective GH secretagogue that stimulates pulsatile GH release without significantly affecting cortisol or prolactin. CJC-1295 without DAC (also called Mod GRF 1-29) is a GHRH analog that amplifies existing GH pulses. The combination of the two is one of the most commonly used GH secretagogue stacks, typically dosed 1-3 times daily via SubQ injection, often before bed to align with natural nocturnal GH release.

Setting Up Your Protocol

A protocol has four core parameters: dose, frequency, route, and timing. For most first-time users, the starting values for these parameters are well-established in community practice and clinical literature.

Timing varies by compound. Healing peptides like BPC-157 are commonly injected in the morning or split between morning and evening. GH secretagogues are often dosed before bed and/or first thing in the morning on an empty stomach — GH release is blunted by elevated blood glucose and insulin, so fasting state is preferred. GLP-1 agonists are typically dosed on the same day each week, with timing within the day being less critical due to their long half-life.

Route for nearly all peptides is subcutaneous injection. The injection technique guide covers site selection, rotation, and step-by-step technique for first-time injectors.

The First Two Weeks

The first two weeks of a peptide protocol are an adjustment period. The compound is building toward steady-state blood levels (which takes approximately 4-5 half-lives of consistent dosing), and the body is adapting to the new input. Setting expectations for this period prevents premature disappointment or unnecessary concern.

What is normal

• Injection site reactions: Minor redness, small bumps at the injection site, and occasional bruising are common and resolve within hours. These are mechanical reactions to the needle, not adverse effects of the compound
• GLP-1 GI effects: Nausea, reduced appetite, and occasional constipation are expected during GLP-1 titration — this is the mechanism of action, not a side effect to be alarmed by. These typically attenuate within 2-4 weeks at each dose level
• GH secretagogue effects: Mild water retention, increased hunger (from ghrelin stimulation with some secretagogues), and improved sleep quality are commonly reported in the first 1-2 weeks
• Healing peptides: No dramatic changes in the first two weeks are typical. BPC-157 and TB-500 work through tissue remodeling processes that operate over weeks, not days

What is not normal

Persistent redness, swelling, or warmth at an injection site that worsens over 24-48 hours rather than improving, systemic fever, or significant unexpected symptoms that were not described in the compound's known effect profile warrant professional evaluation. These presentations are uncommon with proper aseptic technique and quality compounds.

Setting realistic expectations

The most common source of frustration in the first two weeks is expecting visible results too soon. Most peptide effects are gradual. Even GLP-1 agonists, which produce the most immediately noticeable effects (appetite suppression), start at sub-therapeutic doses during the titration phase. For compounds like BPC-157 or GH secretagogues, meaningful subjective changes are more commonly noticed in weeks 3-6 than in days 1-14.

Pharmacokinetically, a compound reaches steady-state blood levels after approximately 4-5 half-lives of consistent dosing. For BPC-157 (half-life ~30 minutes), this happens within hours. For semaglutide (half-life ~7 days), steady state is not reached until approximately 4-5 weeks of weekly dosing. Understanding where your compound sits on this timeline prevents premature conclusions about whether it is "working."

Tracking Your Progress

Tracking is what transforms a protocol from "I think something is happening" to "I can see what is happening." Without data, the only assessment tool is memory and subjective impression — both of which are unreliable, biased toward recent experience, and easily influenced by expectation.

Daily subjective check-ins

A brief daily check-in covering key subjective markers creates a dataset that reveals trends invisible to day-to-day perception. Common markers to track:

• Energy — overall energy level on a 1-5 scale
• Sleep quality — how rested you feel, independent of hours slept
• Mood — baseline emotional state
• Recovery — how recovered you feel from physical activity
• Appetite — particularly relevant for GLP-1 protocols
• Compound-specific markers — soreness for healing protocols, skin quality for GHK-Cu, etc.

The check-in itself takes 30-60 seconds. The value emerges over weeks: a trend line that shows energy gradually improving, or sleep quality stabilizing, provides data-backed evidence that something is changing — or that it is not, which is equally valuable information.

Measurements and photos

For body composition goals, periodic measurements add objective data. Weight (same time, same conditions), waist circumference, and standardized progress photos every 2-4 weeks capture changes that daily perception misses. The scale alone is insufficient — weight fluctuates by 1-3 kg daily from water, food, and glycogen alone.

Bloodwork scheduling

Baseline bloodwork before starting and a follow-up panel at 4-8 weeks provides the most informative comparison. The specific markers depend on the compound — the bloodwork timing guide covers which panels are relevant for each compound category and when to schedule them relative to dosing for accurate trough measurements.

When to Adjust

One of the most common first-protocol mistakes is adjusting too early. Changing dose, frequency, or even abandoning a compound before it has reached steady state and had time to produce effects leads to inconclusive results and wasted compound. The general framework for assessment timing:

• Healing peptides (BPC-157, TB-500): Allow at least 3-4 weeks before assessing. Tissue healing and remodeling processes are gradual. Some users report noticeable changes at 2 weeks, many at 4-6 weeks
• GLP-1 agonists (semaglutide, tirzepatide): The titration schedule itself is an assessment framework. Each dose level is held for 4 weeks before increasing. Appetite and weight changes at each dose inform whether the next titration step is appropriate
• GH secretagogues (Ipamorelin, CJC-1295): Sleep quality improvements are often noticed within 1-2 weeks. Body composition changes require 8-12 weeks of consistent use. IGF-1 bloodwork at 6-8 weeks provides objective data on GH axis stimulation

Signs a protocol is working

For most compounds, the signal is gradual rather than dramatic. Slightly better sleep that accumulates over a week. A subtle improvement in how a nagging injury feels. Appetite reduction that you notice when you realize you forgot to eat lunch. These are typical early signals. Dramatic overnight changes are rare and not the expected pattern for most peptide compounds.

Signs to reconsider

If a compound has been run at an appropriate dose for the recommended minimum duration with no subjective or objective changes, that is informative data. Possible explanations include compound quality, dose inadequacy, or individual non-response. Before increasing dose, many experienced users recommend verifying compound quality (sourcing from a different vendor for comparison) and confirming reconstitution and storage are correct.

Common Beginner Mistakes